Scinai Immunotherapeutics SCNI
NASDAQ SCNI
$0.47 +0.03 (+6.82%)
At close: Nov 9, 2026 · 4:00 PM EST

Scinai Immunotherapeutics (SCNI) EBITDA Margin (2024 - 2026)

Updated

Scinai Immunotherapeutics (SCNI) posted EBITDA Margin of -339.13% for Q2 2026, up 645.90 percentage points from -985.03% a year earlier and up 72.73 percentage points from the prior quarter.

Analysis

Scinai Immunotherapeutics (SCNI) EBITDA Margin (2024 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Scinai Immunotherapeutics was -385.19%, up 202.86 percentage points year-over-year; for FY2025, it was -348.43%, up 713.73 percentage points from FY2024.

  • In prior years, Scinai Immunotherapeutics' EBITDA Margin was -1062.16% in FY2024.
  • The Q2 2026 figure stands as the highest quarterly EBITDA Margin since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn 54.65%
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn 32.68%
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn 46.88%
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn 40.75%
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn 39.77%
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn 46.62%
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn 50.63%
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn 42.49%
10 Scinai Immunotherapeutics 112,563.86 -8.15 Mn -1.25 Mn -339.13%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -339.13%
Mar 31, 2026 -411.86%
Jun 30, 2025 -985.03%
Mar 31, 2025 -207.68%
Dec 31, 2024 -856.31%
Sep 30, 2024 -1,144.05%
API Access

Scinai Immunotherapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SCNI&period=max&api_key=YOUR_API_KEY